1-[2-(4-Methoxyphenyl)ethyl]-4-methylpiperidine | 123469-40-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[2-(4-Methoxyphenyl)ethyl]-4-methylpiperidine
• CAS: 123469-40-9
• 化学式: C₁₅H₂₃NO
• 分子量: 233.35
• InChiKey: DNBKQHWVJJFPSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20160168139A1

  公开（公告）日：2016-06-16

  There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z 2 represents CH or the like; Z 1 represents CR 6 or the like; R 6 represents a hydrogen atom or the like; X 1 represents CHR 7 or the like; R 7 represents a hydrogen atom or the like; X 2 represents CH 2 or the like; R 1 and R 2 are the same as or different from each other, and each of R 1 and R 2 represents a hydrogen atom or the like; R 3 , R 4 , and R 5 are the same as or different from each other, and each of R 3 , R 4 , and R 5 represents a hydrogen atom, NR a R b , or the like; and each of R a and R b represents a hydrogen atom, a C 1-8 alkyl group which may have a substituent, or the like.)

  提供一种由通用式[1A]表示的吗啉衍生物或其盐。 （在该式中，环A代表由通用式[I]表示的环；*代表连接位置；Z 2 代表CH或类似物；Z 1 代表CR 6 或类似物；R 6 代表氢原子或类似物；X 1 代表CHR 7 或类似物；R 7 代表氢原子或类似物；X 2 代表CH 2 或类似物；R 1 和R 2 相同或不同，且R 1 和R 2 中的每一个代表氢原子或类似物；R 3 ，R 4 和R 5 相同或不同，且R 3 ，R 4 和R 5 中的每一个代表氢原子，NR a R b 或类似物；R a 和R b 中的每一个代表氢原子，可能具有取代基的C 1-8 烷基基团，或类似物。）
• [EN] KINASE MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS<br/>[FR] MODULATEURS DE KINASE, COMPOSITIONS PHARMACEUTIQUES ET APPLICATIONS THÉRAPEUTIQUES
  申请人：BIOTHERYX INC

  公开号：WO2021155050A1

  公开（公告）日：2021-08-05

  Provided herein are kinase modulators, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease, disorder, or condition associated with a protein malfunction.

  根据本文件提供的是激酶调节剂，例如，一种公式（I）的化合物，以及它们的药物组合物。此外，还提供了使用它们来治疗、预防或改善与蛋白质功能障碍相关的疾病、障碍或症状的方法。
• HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas.
  申请人：Lixte Biotechnology, Inc.

  公开号：EP2714924B1

  公开（公告）日：2018-03-21
• Benzimidazole-derived compounds use as markers in the case of neurodegenerative diseases
  申请人：Maccioni Baraona Ricardo

  公开号：US20110300072A1

  公开（公告）日：2011-12-08

  Use of benzimidazole-derived compounds of formula (I) according to the following structure, wherein x is a heteroatom selected from N, S, O, P, SO, SO 2 and SO 3 , preferably from N, S and SO 3 and most preferably from N and SO 3 ; n may be 0 or 1, R1 is a group selected from formula (II) and formula (III) and R2 is a group selected from H and formula (IV) since the aforesaid serves for the production of a formulation used as a specific marker in the case of neurodegenerative diseases and tau pathologies.
• US8916132B2
  申请人：——

  公开号：US8916132B2

  公开（公告）日：2014-12-23